Catabasis Pharma (CATB) Tops Q4 EPS by 7c, Beats on Revenues

Note: EPS may not be comparable

Catabasis Pharma (NASDAQ: CATB) reported Q4 EPS of ($0.24), $0.07 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $250 thousand versus the consensus estimate of $130 thousand.

For earnings history and earnings-related data on Catabasis Pharma (CATB) click here.

You May Also Be Interested In

• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• Paramount Global (PARA) Tops Q2 EPS by 480c
• Vislink Technologies Inc. (VISL) Misses Q2 EPS by 7c